Evidence map›Paper›PMID 35677616›Full record

ReviewJournal of multidisciplinary healthcare2022

Generalized Arterial Calcification of Infancy (GACI): Optimizing Care with a Multidisciplinary Approach.

Kenji Kawai, Yu Sato, Rika Kawakami, Atsushi Sakamoto, Anne Cornelissen, Masayuki Mori, Saikat Ghosh, Robert Kutys, Renu Virmani, Aloke V Finn

Abstract readReview
In one paragraph

Review in Journal of multidisciplinary healthcare, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Soft tissue calcifications in chronic kidney disease-beyond the vasculature.Pflugers Archiv : European journal of physiology · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kenji Kawai *CVPath Institute, Gaithersburg, MD, USA.
Yu Sato *CVPath Institute, Gaithersburg, MD, USA.
Rika KawakamiCVPath Institute, Gaithersburg, MD, USA.
Atsushi SakamotoCVPath Institute, Gaithersburg, MD, USA.
Anne CornelissenCVPath Institute, Gaithersburg, MD, USA.
Masayuki MoriCVPath Institute, Gaithersburg, MD, USA.
Saikat GhoshCVPath Institute, Gaithersburg, MD, USA.
Robert KutysCVPath Institute, Gaithersburg, MD, USA.
Renu VirmaniCVPath Institute, Gaithersburg, MD, USA.
Aloke V FinnCVPath Institute, Gaithersburg, MD, USA.

Funding

IL1beta signaling in SMCpromotes beneficial changes in late stage atherosclerotic lesion pathogenesisR01HL141425 · NHLBI · UNIVERSITY OF VIRGINIA · PI OWENS, GARY K · 2019 to 2022
$3.1M
NHLBI NIH HHS R01 HL141425
6 · The paper itself

Abstract

It is very unusual to see evidence of arterial calcification in infants and children, and when detected, genetic disorders of calcium metabolism should be suspected. Generalized arterial calcification of infancy (GACI) is a hereditary disease, which is characterized by severe arterial calcification of medium sized arteries, mostly involving the media with marked intimal proliferation and ectopic mineralization of the extravascular tissues. It is caused by inactivating variants in genes encoding either ENPP1, in a majority of cases (70-75%), or ABCC6, in a minority (9-10%). Despite similar histologic appearances between ENPP1 and ABCC6 deficiencies, including arterial calcification, organ calcification, and cardiovascular calcification, mortality is higher in subjects carrying the ENPP1 versus ABCC6 variants (40% vs 10%, respectively). Overall mortality in individuals with GACI is high (55%) before the age of 6 months, with 24.4% dying in utero or being stillborn. Rare cases show spontaneous regression with age, while others who survive into adulthood often manifest musculoskeletal complications (osteoarthritis and interosseous membrane ossification), enthesis mineralization, and cervical spine fusion. Despite recent advances in the understanding of the genetic mechanisms underlying this disease, there is still no ideal therapy for the resolution of vascular calcification in GACI. Although bisphosphonates with anti-calcification properties have been commonly used for the treatment of CAGI, their benefit is controversial, with favorable results reported at one year and questionable benefit with delayed initiation of treatment. Enzyme replacement therapy with administration of recombinant form of ENPP1 prevents calcification and mortality, improves hypertension and cardiac function, and prevents intimal proliferation and osteomalacia in mouse models of ENPP1 deficiency. Therefore, newer treatments targeting genes are on the horizon. In this article, we review up to date knowledge of the understanding of GACI, its clinical, pathologic, and etiologic understanding and treatment in support of more comprehensive care of GACI patients.

Indexed as

ATP binding cassette subfamily C member 6ectonucleotide pyrophosphatase/phosphodiesterase 1generalized arterial calcification of infancyvascular calcification

Identifiers

PMID35677616
PMCPMC9167688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.